Literature DB >> 8128675

Novel antithrombotic therapy.

G M Rodgers1.   

Abstract

The prospects for more effective and safe antithrombotic therapy appear promising. I have presented only a portion of all novel antithrombotic agents currently under basic and clinical investigations. A discussion of additional new antithrombotic drugs is presented elsewhere.

Mesh：

Substances：

Year:  1993        PMID： 8128675      PMCID： PMC1022453     

Source DB:  PubMed          Journal:  West J Med        ISSN： 0093-0415


  31 in total

Review 1.  Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.

Authors:  J Hirsh; J E Dalen; D Deykin; L Poller
Journal:  Chest       Date:  1992-10       Impact factor: 9.410

Review 2.  Aspirin and other platelet-active drugs. The relationship between dose, effectiveness, and side effects.

Authors:  J Hirsh; J E Dalen; V Fuster; L B Harker; E W Salzman
Journal:  Chest       Date:  1992-10       Impact factor: 9.410

Review 3.  Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range.

Authors:  J Hirsh; J E Dalen; D Deykin; L Poller
Journal:  Chest       Date:  1992-10       Impact factor: 9.410

Review 4.  Structure, function and evolutionary relationship of proteins containing a disintegrin domain.

Authors:  C P Blobel; J M White
Journal:  Curr Opin Cell Biol       Date:  1992-10       Impact factor: 8.382

5.  Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone.

Authors:  S R Hanson; L A Harker
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

6.  The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke.

Authors:  M Gent; J A Blakely; J D Easton; D J Ellis; V C Hachinski; J W Harbison; E Panak; R S Roberts; J Sicurella; A G Turpie
Journal:  Lancet       Date:  1989-06-03       Impact factor: 79.321

7.  Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.

Authors:  R D Hull; G E Raskob; G F Pineo; D Green; A A Trowbridge; C G Elliott; R G Lerner; J Hall; T Sparling; H R Brettell
Journal:  N Engl J Med       Date:  1992-04-09       Impact factor: 91.245

8.  Optimal therapeutic level of heparin therapy in patients with venous thrombosis.

Authors:  R D Hull; G E Raskob; D Rosenbloom; J Lemaire; G F Pineo; B Baylis; J S Ginsberg; A A Panju; P Brill-Edwards; R Brant
Journal:  Arch Intern Med       Date:  1992-08

9.  A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. A randomized, double-blind study.

Authors:  A G Turpie; M Gent; R Côte; M N Levine; J S Ginsberg; P J Powers; J Leclerc; W Geerts; R Jay; J Neemeh
Journal:  Ann Intern Med       Date:  1992-09-01       Impact factor: 25.391

10.  Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor.

Authors:  M Heras; J H Chesebro; W J Penny; K R Bailey; L Badimon; V Fuster
Journal:  Circulation       Date:  1989-03       Impact factor: 29.690
View more
  1 in total

1.  Role of platelet adhesion and aggregation in antithrombotic therapy.

Authors:  Z M Ruggeri
Journal:  West J Med       Date:  1993-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.